S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Instantly Find Hidden Trade Opportunities (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Instantly Find Hidden Trade Opportunities (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Instantly Find Hidden Trade Opportunities (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Instantly Find Hidden Trade Opportunities (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Instantly Find Hidden Trade Opportunities (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Instantly Find Hidden Trade Opportunities (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Instantly Find Hidden Trade Opportunities (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Instantly Find Hidden Trade Opportunities (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Instantly Find Hidden Trade Opportunities (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Instantly Find Hidden Trade Opportunities (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Instantly Find Hidden Trade Opportunities (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Instantly Find Hidden Trade Opportunities (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:AEZS

Aeterna Zentaris (AEZS) Stock Forecast, Price & News

$2.78
0.00 (0.00%)
(As of 05/31/2023 ET)
Compare
Today's Range
$2.75
$2.82
50-Day Range
$2.45
$3.23
52-Week Range
$2.32
$8.63
Volume
9,188 shs
Average Volume
14,058 shs
Market Capitalization
$13.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Aeterna Zentaris MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Aeterna Zentaris in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.41) to ($2.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.43 out of 5 stars

Medical Sector

945th out of 1,006 stocks

Pharmaceutical Preparations Industry

469th out of 492 stocks


AEZS stock logo

About Aeterna Zentaris (NASDAQ:AEZS) Stock

Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Stock News Headlines

AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com
See More Headlines
Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Company Calendar

Last Earnings
3/23/2023
Today
5/31/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AEZS
Employees
11
Year Founded
N/A

Profitability

Net Income
$-22,730,000.00
Pretax Margin
-389.41%

Debt

Sales & Book Value

Annual Sales
$5.64 million
Book Value
$6.43 per share

Miscellaneous

Free Float
4,851,000
Market Cap
$13.49 million
Optionable
Optionable
Beta
1.38

Social Links


Key Executives

  • Klaus Wolfgang Paulini
    President, Chief Executive Officer & Director
  • Giuliano La Fratta
    Chief Financial Officer & Senior Vice President
  • Michael Teifel
    Chief Scientific Officer & Senior Vice President
  • Nicola Ammer
    Chief Medical Officer & Senior Vice President
  • Patricia Zahn
    Director-Administrative Services & Human Resources













AEZS Stock - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings
or view top-rated stocks.

How have AEZS shares performed in 2023?

Aeterna Zentaris' stock was trading at $3.18 at the start of the year. Since then, AEZS shares have decreased by 12.7% and is now trading at $2.7750.
View the best growth stocks for 2023 here
.

Are investors shorting Aeterna Zentaris?

Aeterna Zentaris saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 81,700 shares, a decrease of 14.4% from the April 30th total of 95,400 shares. Based on an average daily volume of 15,800 shares, the short-interest ratio is presently 5.2 days. Currently, 1.7% of the company's shares are sold short.
View Aeterna Zentaris' Short Interest
.

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our AEZS earnings forecast
.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) posted its earnings results on Thursday, March, 23rd. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $0.09. The biopharmaceutical company earned $2.49 million during the quarter, compared to analysts' expectations of $1.06 million.

When did Aeterna Zentaris' stock split?

Shares of Aeterna Zentaris reverse split before market open on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?
What is Aeterna Zentaris' stock symbol?

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Who are Aeterna Zentaris' major shareholders?

Aeterna Zentaris' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Susquehanna International Group LLP (0.00%).

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $2.78.

How much money does Aeterna Zentaris make?

Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $13.49 million and generates $5.64 million in revenue each year. The biopharmaceutical company earns $-22,730,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis.

How can I contact Aeterna Zentaris?

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (418) 652-8525, via email at ir@aezsinc.com, or via fax at 418-948-9191.

This page (NASDAQ:AEZS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -